Accelrys Releases New Modeling and Simulation Software for Life Science Researchers With Discovery Studio(R) 2.5

Accelrys Releases New Modeling and Simulation Software for Life Science Researchers With Discovery Studio(R) 2.5

Innovative Science in the Areas of Small Molecule Modeling, Fragment-Based Design, Transmembrane Proteins, and Antibody Modeling Sets New Standard for Life Science Research and Development

SAN DIEGO, CA, Jun 29, 2009 (MARKETWIRE via COMTEX) -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific business intelligence software and services, announced the release of Discovery Studio(R) 2.5, the most advanced computational chemistry and biology software environment for drug discovery available today. To meet the modern day challenges of drug discovery projects, this release features major new scientific developments, and a focus on enhancing user experience by providing significant usability enhancements, with a fully customizable interface and improved integration with Pipeline Pilot. Because it is built upon Pipeline Pilot, Accelrys' scientific operating platform, Discovery Studio 2.5 is an extensible virtual discovery environment that lets researchers integrate any tool they need to create solutions that are uniquely tailored to fit their research process.

"The new version of Discovery Studio is robust and offers a wide range of functionality," said Manel Lopez, Ph.D., senior scientist at Almirall, a leading pharmaceutical company headquartered in Barcelona, Spain. "I really like the customizable Discovery Guides panel. The new transmembrane protein modeling capabilities of the software are impressive, and will contribute greatly to my research."

About Discovery Studio 2.5

Discovery Studio 2.5 streamlines collaboration and increases research productivity with key enhancements in the following core areas:


New scientific developments in the area of small molecule modeling, fragment-based design, transmembrane protein analysis, and antibody modeling.
Enhanced customizability through new Discovery Guides which allows users to combine any scientific algorithm and/or functionality in DS to create a personalized taskflow.
Improved Pipeline Pilot integration, allowing users to access scientific components and protocols to customize workflows, thus providing flexibility and extensibility of the scientific methods. Subsequently, these methods are easily deployed within a group via a Web Port or Microsoft(R) Sharepoint for effective communication and results-oriented collaboration.
Access to the popular GOLD docking program, licensed by CCDC, allowing GOLD users to benefit from the robust features of Discovery Studio for model preparation and docking analysis.

The Discovery Studio architecture also provides access to products developed by partners in Accelrys' ISV ecosystem allowing seamless and sophisticated integration of any third party algorithm.

"Discovery Studio 2.5 represents a significant milestone in the evolution of Accelrys' life science modeling and simulation software," said Frank Brown, chief science officer of Accelrys. "The breadth of validated science now on our platform allows for customizing and automating almost any complex modeling task. This makes the process more robust and easier to use simultaneously, thereby extending the reach of this capability to many more scientists."

For more information about Discovery Studio 2.5 or to download a free trial of Discovery Studio, please visit http://accelrys.com/products/discovery-studio/

About Accelrys, Inc.

Headquartered in San Diego, California, Accelrys develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its scientific business intelligence platform underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit http://accelrys.com/

Forward-Looking Statements

This press release contains forward-looking statements. Such statements, including statements relating to the Company's products, their features, and their impact upon our customers' organizations, are subject to risks and uncertainties including, but not limited to, the risk that our products will not be successfully developed, achieve market acceptance, have the anticipated impact upon our customers' organizations, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.